Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Manette T. Niu"'
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 5, Iss 1, Pp 1-4 (2019)
Abstract Sipuleucel-T, an autologous active cellular immunotherapy, is indicated for the treatment of asymptomatic or minimally symptomatic castration-resistant prostate cancer. The U.S. Food and Drug Administration Adverse Event Reporting System (FA
Externí odkaz:
https://doaj.org/article/94bdf3f6f7f446579fe5e898d2cd2c0f
Autor:
John R. Su, Julianne Gee, Manette T. Niu, Diane Gubernot, Tom T. Shimabukuro, Pedro L. Moro, Theresa Harrington, Steven A. Anderson, Michael M. McNeil, Sarah D. Bennett, Christine K. Olson, Amelia Jazwa, Richard A. Forshee, Jane Baumblatt, Jonathan Duffy, Satoshi Kamidani, Karen R. Broder, Lakshmi Panagiotakopoulos
Publikováno v:
Vaccine. 39:3666-3677
The Coronavirus Disease 2019 (COVID-19) pandemic has had a devastating impact on global health, and has resulted in an unprecedented, international collaborative effort to develop vaccines to control the outbreak, protect human lives, and avoid furth
Publikováno v:
Drugs-Real World Outcomes
Background Digoxin immune fab products, DigiBind and DigiFab, are antidotes for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. Although approved by the US Food and Drug Administration (FD
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 5, Iss 1, Pp 1-4 (2019)
Journal of Pharmaceutical Health Care and Sciences
Journal of Pharmaceutical Health Care and Sciences
Sipuleucel-T, an autologous active cellular immunotherapy, is indicated for the treatment of asymptomatic or minimally symptomatic castration-resistant prostate cancer. The U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) rece
Publikováno v:
American journal of hematologyREFERENCES. 96(9)
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor T-cell therapy, tisagenlecleucel, in August 2017. We sought to describe adverse events (AEs) reported to the FDA Adverse Event Reporting System (FAERS) for tisag
Publikováno v:
Cancer
Publikováno v:
Vaccine. 27:290-297
During the period March 1, 1998 to January 14, 2007, approximately 6 million doses of Anthrax vaccine adsorbed (AVA) vaccine were administered. As of January 16, 2007, 4753 reports of adverse events following receipt of AVA vaccination had been submi
Autor:
Gina T. Mootrey, Elaine Jong, Alejandra Gurtman, Theodore F. Tsai, Michael Martin, Jeff Altman, Manette T. Niu, Martin S. Wolfe, Elizabeth D. Barnett, David O. Freedman, Phyllis E. Kozarsky, Mary E. Wilson, Jan E. Patterson, Michele Barry, Martin S. Cetron, Bradley A. Connor, Leisa H. Weld, Robert T. Chen, Bradley R. Sack, Vernon E. Ansdell, Russell McMullen
Publikováno v:
Emerging Infectious Diseases, Vol 7, Iss 6, Pp 945-951 (2001)
Emerging Infectious Diseases
Emerging Infectious Diseases
In 1998, the Centers for Disease Control and Prevention was notified of severe illnesses and one death, temporally associated with yellow fever (YF) vaccination, in two elderly U.S. residents. Because the cases were unusual and adverse events followi
Publikováno v:
Vaccine. 19:4627-4634
The Vaccine Adverse Event Reporting System (VAERS) is the US passive surveillance system monitoring vaccine safety. A major limitation of VAERS is the lack of denominator data (number of doses of administered vaccine), an element necessary for calcul
Publikováno v:
Journal of Infectious Diseases. 178:80-91
A multicenter, double-blind, placebo-controlled trial randomized 28 patients with primary (acute) human immunodeficiency virus (HIV)-1 infection (PHI) to receive zidovudine, 1000 mg daily, or placebo for 24 weeks. At week 48, compared with placebo pa